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the combination may be found to have an undesirable toxicity profile, which con-
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but with a larger number of patients assigned to safe combinations.
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3Abstract
In traditional schedule or dose-schedule finding designs, patients are assumed to receive
their assigned dose-schedule combination throughout the trial even though the combination
may be found to have an undesirable toxicity profile, which contradicts actual clinical
practice. Since no systematic approach exists to optimize intra-patient dose-schedule as-
signment, we propose a Phase I clinical trial design that extends existing approaches that
optimize dose and schedule solely among patients by incorporating adaptive variations
to dose-schedule assignments within patients as the study proceeds. Our design is based
on a Bayesian non-mixture cure rate model that incorporates multiple administrations
each patient receives with the per-administration dose included as a covariate. Simulations
demonstrate that our design identifies safe dose and schedule combinations as well as the
traditional method that does not allow for intra-patient dose-schedule reassignments, but
with a larger number of patients assigned to safe combinations.
Keywords: Bayesian statistics; Clinical trials; Dose-finding study; Dose-escalation study;
Non-mixture cure model
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41. INTRODUCTION
Traditional Phase I clinical trials seek to identify the maximum-tolerated dose (MTD)
among a set of discrete doses by characterizing a patient’s outcome as a binary indicator of
whether the patient experiences a dose-limiting toxicity (DLT) within a fixed duration of
time. The MTD is the dose at which the probability of having a DLT is near a predefined
target (usually 0.20-0.40). A DLT is typically defined as a Grade 3 or higher toxicity
(National Cancer Institute 2003) that prevents further treatment of the patient. Of the
various methods for traditional Phase I trials, the Continual Reassessment Method (CRM)
of O’Quigley, Pepe, and Fisher (1990) is one of the most popular model-based designs
that update the MTD estimate adaptively. Numerous extensions to the CRM have been
proposed, including the Time-to-Event CRM (TITE-CRM) of Cheung and Chappell (2000)
to account for incomplete follow-up of patients and the later generalization of Braun (2005)
to adapt the TITE-CRM for early- and late-onset DLTs.
Contrary to conventional Phase I designs seeking to find the MTD with a fixed schedule
of administrations, new designs have been proposed to identify the maximum-tolerated
schedule (MTS) among a set of pre-specified schedules when the per-administration dose is
fixed. Schedule-finding studies are especially important when the agent is given at a fixed
dose repeatedly in a sequence of administrations and long-term cumulative toxicities are
of interest. Braun, Zheng, and Thall (2004) proposed an innovative design to model the
time to toxicity rather than a binary outcome using a triangular hazard model for each
administration to determine the MTS. Liu and Braun (2009) developed a more flexible
model for the cumulative hazard of a DLT by introducing a non-mixture cure rate model
and a smooth hazard function.
While the aforementioned schedule-finding designs are useful, it is obvious that a better
design would simultaneously optimize the dose and schedule. For this, Braun et al. (2007)
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5developed the first design for dose-schedule-finding by extending the work of Braun et al.
(2004) to incorporate different triangular hazard functions for each dose. However, as noted
by Liu and Braun (2009), the method of Braun et al. (2004) can be inflexible mainly due
to its computational difficulty, the finite support of the triangular hazard function and the
difficulties with including patient-level or administration-level covariates.
Thus, the first contribution of our current work is to generalize the methods of Liu and
Braun (2009) to simultaneously optimize the dose and schedule assigned to each patient.
Specifically, we extend their Bayesian non-mixture cure model by incorporating the per-
administration dose as a covariate for modeling the cure fraction to allow for multiple dose
levels. In addition, we derive a non-mixture cure rate model through a competing risks
approach to accommodate multiple administrations one patient may receive.
A second limitation of existing model-based adaptive Phase I designs is that they only
determine the assignment for the next patient or group of patients by using the most
recent model estimates. What these designs fail to do is to re-examine the assignments
of patients who are still receiving treatment and may benefit from a change to their
assignment, such as a higher dose at the next administration or increasing the number
of planned administrations at the current dose. It is important to introduce intra-patient
dose and/or schedule reassignment when necessary, especially for the patients enrolled early
in a trial since they are more likely to receive a suboptimal dose or schedule. Although the
model of Braun et al. (2007) could allow the possibility that the patient’s planned dose for
each administration to be changed, both the benefit of intra-patient dose change and how
to reassign intra-patient dose and/or schedules are areas that have not been studied. The
second contribution of our work is to adaptively optimize the dose and schedule assignments
both among patients and within patients. While new patients are given the most recent
maximum-tolerated dose-schedule combination (MTC) estimate, our approach also re-
evaluates the estimated DLT rate for the current assignment of each enrolled patient and
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6automatically determines whether dose-schedule reassignment is needed. Patient accrual,
data monitoring, and outcome-adaptive decision making are done continuously throughout
the trial under a Bayesian formulation. We describe the probability model and the dose-
schedule-finding algorithm in Section 2, and we illustrate the proposed design in the context
of a real trial and present a simulation study in Section 3. We conclude with a brief
discussion in Section 4.
2. PROBABILITY MODEL
2.1 Preliminary Notation
Typical dose-schedule finding trials aim to find the MTC within a J ×K matrix consisting
of J per-administration doses and K nested schedules. We denote the administration times
for schedule k, k = 1, . . . , K, as s(k) = {s1, s2, . . . , smk} such that s
(1) ⊂ s(2) ⊂ · · · ⊂ s(K)
and m1 < m2 < · · · < mK , where mk is the number of administrations for schedule
k. For example, let (5+, 24−) denote a course of administrations at each of the first 5
days followed by 24 days of rest. If the first schedule is comprised of one course, we have
s(1) = {0, 1, 2, 3, 4}. Since schedule 2 consists of two courses with the additional course
starting 28 days after the beginning of s(1), we have s(2) = {0, 1, 2, 3, 4, 28, 29, 30, 31, 32} ={
s(1), s(1) + 28
}
, and so on. Even though we focus on nested schedules that have natural
orders and hence are of interest to the clinicians, our methods work for non-nested schedules
as well. Ideally, we plan to give dose j = 1, 2, . . . J , at each administration in s(k), and we
let d(k)j denote the vector of k elements, each of which is dj.
The number of subjects enrolled by the end of the trial is N and each subject will
be followed up to the maximum follow-up time ω, which is determined by the clinical
investigators and is a clinically meaningful duration of time that is sufficiently late enough
to observe DLTs attributed to the longest schedule. A target DLT rate η is also elicited
from clinicians and is defined as the targeted probability of cumulative toxicity by ω.
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7Note that d(k)j and s
(k) represent the combinations of doses and schedule that are possible
assignments to each patient as they enter the study. In contrast, at any point in the study,
the actual number of administrations and the dose at each administration for each patient
may differ from each of those possible combinations. To make this concept distinct, we let
si = {si,1, . . . , si,mi} , i = 1, . . . , N, denote the successive times at which patient i receives
the agent and let di = {di,1, . . . , di,mi} where di,l ∈ {1, . . . , J} and l = 1, . . . ,mi denote the
per-administration doses for patient i at the administration times si.
Let Wi denote the study time when patient i enters the trial and we define W1 = 0,
which is the starting time of the trial. We further define Yi as the study time when patient
i experiences a DLT. We will observe a DLT for patient i if Wi < Yi ! Wi + ω; otherwise,
patient i will complete their follow-up without DLT being observed for the purposes of
the study. At any study time t ∈ [Wi,Wi + ω], the follow-up time for patient i is Ui =
min(t, Yi) −Wi and the follow-up time for administration l of patient i is νi,l = Ui − si,l,
1 ! l ! mk for a certain k determined by the schedule assigned to patient i. If patient i
has not yet experienced a DLT, i.e., t < Yi, we define the indicator of censoring Ci = 0.
Once DLT is observed, Ci = 1.
2.2 Model for Time-to-DLT After a Single Administration
As noted by Liu and Braun (2009), a significant proportion of patients are “cured,” i.e. never
experience DLTs after a single administration. Thus, they chose to model the time-to-DLT
for a single administration using a non-mixture cure model. Specifically, we take a standard
cumulative distribution function F (ν|φ) with parameters φ, with a corresponding density
function f(ν|φ), and scale F (ν|φ) by a parameter θ > 0 to create the respective survival and
hazard functions S(ν|θ,φ) = exp[−θF (ν|φ)] and g(ν|φ, θ) = θf(ν|φ). We adopt S(ν|θ,φ)
as the probability of no DLT by follow-up time ν after a single administration and interpret
θ as a cure rate parameter because the cure fraction S(∞) = exp(−θ) is determined solely
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8by θ. The Time-to-Event CRM (TITE-CRM) of Cheung and Chappell (2000) for traditional
dose-finding can be viewed as a mixture cure model for the time-to-DLT, as outlined in
Braun (2005). However, we have chosen to use a non-mixture cure rate model instead of
a mixture cure model because the latter does not have a proportional hazards structure
and is less feasible for Bayesian computations (Chen, Ibrahim, and Sinha 1999; Tsodikov,
Ibrahim, and Yakovlev 2003).
However, the non-mixture cure model used by Liu and Braun (2009) must be extended
to allow the cure fraction to vary by dose. To that end, we model the cure rate fraction
for administration l of patient i as log(θi,l) = β0 + exp(β1)di,l,−∞ < β0, β1 < ∞, so that
θi,l > 0. Note that we exponentiate β1 > 0 to ensure that the probability of DLT after a
single administration increases with dose. As a result, the respective hazard and survival
functions for a single administration l are g(νi,l|β,φ) = θi,lf(νi,l|φ) and S(νi,l|β,φ) =
exp[−θi,lF (νi,l|φ)], in which β = (β0, β1).
In order to fully specify the time-to-DLT after a single administration, we need to chose
a specific form for f(νi,l|φ). As recommended by Liu and Braun (2009), we use a two-
parameter Weibull density f(νi,l|φ) = exp(−γ)αν
α−1
i,l exp
[
−ναi,l exp(−γ)
]
with φ = (α, γ).
Such a choice has biologic appeal because the resulting hazard function increases with
time to a certain time point and then attenuates afterward, as was suggested by clinical
investigators in our application. Mathematically, we expect the mode of the hazard function
to exist at exp(γ/α)(1 − 1/α)1/α, and we assume α > 1 so that the mode exists. We also
considered modeling φ as a function of dose like we did for the cure fraction, but we found
in simulations (results not shown) that this added level of complexity to our model offered
no benefit to the performance of our design. In addition, such a model would eliminate the
proportional hazards structure of our model.
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92.3 Model for Time-to-DLT After Multiple Administrations
We employ a competing risks cure rate model by treating yi,l, the time to the DLT after
administration l of patient i, as a latent variable to incorporate the multiple administrations
received by each patient. The study time when patient i experiences a DLT is then defined
as the random variable Yi = Wi +min {(s1 + yi,1), . . . , (smi + yi,mi)}. Therefore, under the
assumption of independence of yi,1, . . . , yi,mi , the survival function for patient i at study
time t ∈ [Wi,Wi + ω], is given by
Si(t|β,φ, si,di) = Pr(Yi > t) =
mi∏
l=1
S(νi,l|β,φ) = exp
{
−
mi∑
l=1
θi,lF (νi,l|φ)
}
(1)
and the density function is given by
fi(t|β,φ, si,di) =
[
mi∑
l=1
θi,lF (νi,l|φ)
]
exp
{
−
mi∑
l=1
θi,lF (νi,l|φ)
}
(2)
where θi,l = exp(β0 + β1di,l) is the cure parameter and νi,l = min(t, Yi) − (Wi + si,l) is
the follow-up time for administration l of patient i. The hazard function at study time t
is given by hi(t; |β,φ, si,di) =
∑mi
l=1 θi,lF (νi,l|φ), which indicates the cumulative effect of
multiple administrations.
The assumption that the times-to-DLT after each administration, yi,1, . . . , yi,mi , are in-
dependent for the mi administrations of the same patient i might not hold, although the
actual amount of correlation is not testable (Tsiatis 1975). A more general model could be
based on an Archimedean copula-type model, which can also be regarded as a frailty model
with a cure fraction (Hougaard 2000). For example, the above survival function could be
generalized to
Soi (t|β,φ, si,di) = exp
{
−(
mi∑
l=1
[θi,lF (νi,l|φ)]
1/ξ)ξ
}
,
which is a Gumbel copula model with a correlation parameter ξ, in which ξ = 0 indicates
independent DLT times. In this paper, we will assume independence for our model since
it is simple and we feel that copula models could possibly impose strong and untestable
assumptions on the correlation structure of DLT times.
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Another assumption of our model is the log-linearity for modeling the relationship be-
tween the cure parameter θ and dose. This assumption could be relaxed by either adding
more parameters in the model to allow for the non-linearity or using a Bayesian model
averaging approach among differing models (Raftery, Madigan, and Hoeting 1997; Ying
and Yuan 2009). However, we feel that the log-linear model should be adequate in many
settings for identifying the MTC since the sample size is usually small in Phase I trials and
the overall model fit is not our primary interest (O’Quigley et al. 1990).
From this notation, the likelihood function can be derived with ease. By study time
t which is determined independently of time-to-DLT, we denote the number of patients
currently in the study as n and for each enrolled patient, we know si and di, the respective
time and dose for each administration, νi = {νi,1, . . . , νi,mi}, the follow-up times for each
administration, and Ci, which indicates whether or not a DLT was observed for patient i.
Based on the above information, Equations (1) and (2), the likelihood is given by
Ln(β,φ; t, si,di) =
n∏
i=1
Si(t|β,φ, si,di)
1−Cifi(t|β,φ, si,di)
Ci (3)
After determining the prior distributions for β and φ, we can compute posterior quanti-
ties via adaptive Markov Chain Monte Carlo (MCMC) methods (Rosenthal 2007). Those
posterior quantities will be used to identify the dose-schedule assignment for a new patient
and a possibly new dose-schedule assignment for an existing patient as described in Section
2.5.
2.4 Establishing Prior Distributions
For the two parameters of the cure fraction, β, we assign independent Gaussian distributions
with prior mean and prior variance (µ0, σ20) for β0 and (µ1, σ
2
1) for β1. In order to determine
values for the prior means µ0 and µ1, we ask the investigators to provide the “skeleton”
P , which is a J × K matrix of a priori estimates of the DLT rates by ω for all dose-
schedule combinations, in which element (j, k), denoted Pjk, corresponds to the combination
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of dose j and schedule k. We then fit the linear regression model log(− log[1 − Pjk]) =
log(mk) + b0 + exp(b1)dj and use the ordinary least square estimates bˆ0 and bˆ1 as the
respective values for µ0 and µ1.
For the two parameters of the hazard, φ = (α, γ), we have chosen to make α fixed to
maintain a parsimonious model and limit the number of parameters to estimate. In addition,
preliminary simulations (results not shown) indicated that there was no meaningful change
in operating characteristics when assigning a prior distribution to α. However, because the
mode of the hazard for a single administration monotonically increases with γ, estimation
of γ is important to the performance our algorithm. Therefore, we assign a Gaussian prior
distribution for γ with mean µγ and variance σ2γ. To determine values for α and µγ, we
apply the method outlined in Liu and Braun (2009) for each dose and calculate the average.
If the resulting value for α < 1, we set α = 1.01, so that the mode exists.
It is important to carefully calibrate the prior variances σ21, σ
2
2 and σ
2
γ as we can imagine
that Phase I trials are usually sensitive to prior variances due to the small sample size.
The prior variances should not be too small, otherwise the prior information dominates
the trial. However, they cannot be too large either since we hope to incorporate the prior
information for possibly more accurate estimation. We recommend calibrating the prior
variances through simulations using a few different skeletons and prior variances. The
prior variance that is the most insensitive to skeletons and leads to the best operating
characteristics will be used for a real trial. We present an example of variance calibration
related to the simulations of Section 3..
2.5 Algorithm for Adaptive Assignments for New Patients and
Reassignments for Enrolled Patients
The algorithm for assigning a dose-schedule combination to a new patient i is similar
to that used in the CRM and many other Phase I designs. When a new patient enters
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the study, for every combination of a dose j and a schedule k, we compute pˆjk = 1 −
S(ω+Wi|φˆ, βˆ, s(k),d
(k)
j ), the estimated DLT rate by the maximum follow-up time ω, where
φˆ and βˆ are the respective posterior means of φ and β. Given a desired DLT rate η,
the dose-schedule combination that minimizes the distance |pˆjk − η|, which we denote
(j∗, k∗) is assigned to the next patient, subject to one restriction. Both j∗ and k∗ cannot
simultaneously be respectively more than one dose higher than ji−1, the dose assigned to
the most recently enrolled patient, and ki−1, the schedule assigned to the most recently
enrolled patient. Even though we use a “no-skipping” rule for dose-schedule escalation
among successive patients, there is no such rule when it comes to de-escalation. We place
no restriction on escalation of dose and schedule within a patient, which some may view as
overly aggressive, but in the simulation results presented in Section 3.3, we see no evidence
of a higher than desired rate of DLTs. We also ran simulations in which the among-patient
restriction on escalation to also applied within-patient (results not shown). We saw little
change to the results presented in Table 4, except that patient assignments to acceptable
combinations tended to lessen with the restriction than without it. Lastly, if necessary, we
could implement a stopping rule to terminate a trial when the accumulated data indicates
that all combination of doses and schedules are overly toxic. One such rule would be to
terminate the trial if the estimated DLT rate for the lowest combination is above a threshold,
for instance, η + 0.1.
We emphasize that reassignment of dose and/or schedule does not apply to patients who
have experienced DLT, nor to those who finished their originally assigned treatment, nor
those whose treatment was terminated early. For the remaining n∗ ! n patients who are still
planning to receive additional administrations, we compute pˆ$ = 1−S(ω+W$|φˆ, βˆ, s$,d$),
which is the estimated DLT rate of the administrations received so far by patient * =
1, 2, . . . n∗. We immediately terminate the treatment of any patient * for whom pˆ$ " η+0.1,
as they have already received a combination that appears to be overly toxic and further
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treatment would be unethical. Once the treatment is terminated, no additional adminis-
trations will be given to the patient but this patient is still under follow-up until a DLT
occurs or the maximum follow-up time ω is reached.
For each of the remaining patients for whom pˆ$ < η + 0.1, we need to consider how
many more administrations might be given and which dose would be given at each of those
administrations. Specifically, if m$ is the number of administrations received so far, we
compute δk$ = (mk −m$), for each schedule k, including the schedule to which the patient
was originally assigned. Among all schedules with δk$ > 0, let s
(k)
$+ denote the remaining
administration times for schedule k that could still be assigned to patient *. We consider
the combination of each s(k)$+ with each dose j and let d
(jk)
$+ denote the remaining dose
assignments, which is a vector of δk$ elements each with the value dj. We then compute
P (jk)$ = 1 − S(ω +W$|φˆ, βˆ, [s$, s
(k)
$+ ], [d$,d
(jk)
$+ ]), which is the probability of DLT by ω for
patient * for each of these possible reassignments appended to what he has already received.
We will reassign patient * according to whichever P (jk)$ is closest to the targeted DLT rate,
η. We emphasize again that one of the possible “reassignments” is simply the assignment
currently belonging to patient *.
To clarify our notation, we consider a hypothetical study of J = 3 doses and K = 5
schedules in which schedule k is comprised of k consecutive (5+, 24−) courses as described
in Section 2.1. Imagine that a new patient is to be enrolled in the study and that we
have an enrolled patient * who was assigned to schedule 3, has not yet experienced a
DLT, and has respective administration times and doses for each administration s$ =
{0, 1, 2, 3, 4, 28, 29, 30, 31, 32, 56, 57} and d$ = {8, 8, 8, 8, 8, 16, 16, 16, 16, 16, 32, 32} mg/m2.
As each schedule had a total of five planned administrations, we see that patient * has com-
pleted two courses and has three administrations remaining in her third course. Assuming
that the treatment received so far does not have an estimated DLT rate 10 points above
the target, Table 1 delineates the nine possible remaining assignments that could now be
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given to patient *. Whichever of these nine combinations, when appended to s$ and d$,
leads to an estimated DLT rate by ω closest to the target DLT rate is the reassignment
given to patient *.
[Table 1 about here.]
This example emphasizes the fact that we attempt to keep the dose constant within a
patient as much as possible, i.e. each administration for a patient will be at the same dose
until a reassignment occurs. Thus, the hypothetical patient * described above had already
received two previous changes to her assignment, as her dose was increased from 8 mg/m2,
then to 16 mg/m2, and then again to 32 mg/m2. Of course one could consider a setting in
which the best treatment plan would be contrary to this, i.e. perhaps alternating back-and-
forth between two doses. However, such a treatment plan, or one that considers any of the
J doses at each administration period would be infeasible in practice and would likely lead
to treatment errors if the treatment plans assigned to several patients were all different and
impossible to remember.
Furthermore, we have chosen to only consider reassignments when a new patient is
enrolled. This certainly is not the only benchmark at which we might consider reassigning
patients. For example, we might instead (or also) re-evaluate the data collected so far each
time a patient completes their follow-up, either by reaching ω without a DLT or experiencing
a DLT sometime before ω. Or we could re-evaluate the data each time a patient completes
a course, thereby allowing a course-by-course evaluation for every patient. And if we truly
wanted to optimize the treatment of every patient in the study, it would seem most sensible
to evaluate each patient after every single administration. However, most of these alternate
approaches are unrealistic in practice as the frequency of the necessary computations
would become administratively impossible. On the opposite end of the spectrum, we could
administratively set times, i.e. every three months, when we might consider reassignments
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that have nothing to do with patient outcomes but makes the process of re-assignment
known before the trial begins. However, we feel our approach of re-evaluating assignments
when each new patient is enrolled is a good compromise between optimizing the treatment
of each patient as much as possible and maintaining a feasible level of computation.
2.6 Conduct of the Trial
We plan on enrolling a maximum of N patients in the trial, and each patient will be followed
for ω days after enrollment. The first patient is enrolled at study time t = 0 and is assigned
to the shortest schedule (k = 1) with the lowest dose (j = 1). When patient i = 2, . . . , N
is to be enrolled in the study at study time t, we perform the following steps:
(1) Place each enrolled patient i
′
= 1, 2, . . . i into one of two groups, either those without
DLT or those with DLT;
(2) For patients without DLT, record:
(i) Ci′ = 0, indicating no DLT
(ii) Ui′ = min(ω, t −W − i), the length of follow-up for a patient enrolled at study time
Wi′ ;
(3) For patients with DLT, record:
(i) Ci′ = 1, indicating DLT
(ii) Ui′ = Yi′ −Wi′ , in which Yi′ is the study time at which DLT occurred;
(4) For all enrolled patients, record si′ , the vector of times of each administration received,
and di′ , the vector of doses given at each administration;
(5) Use the information recorded from (2)-(4) above to compute the likelihood given in
Equation (3). Specifically, patients without DLT will contribute an amount given in
Equation (1) and patients with DLT will contribute an amount given in Equation (2);
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(6) Combine the likelihood with the prior distributions described in Section 2.4 to compute
the posterior means of φ and β;
(7) For all enrolled patients, apply the methods described in Section 2.5 to determine whether
to assign a new dose and/or schedule or terminate their treatment altogether;
(8) Determine the dose and schedule assignment for patient i using the methods described
in Section 2.5;
(9) Once all N patients have been enrolled, use all accumulated data to compute final
posterior estimates of the DLT rates of each dose and schedule combination and select
the combination with estimated DLT rate closest to η as the optimal combinations
3. APPLICATION
3.1 Simulation Design
We study our design in simulations based upon the motivating example of Braun et al.
(2007) in patients with acute myelogenous leukemia (AML). There are J = 3 doses of
interest: 8, 16 and 24 mg/m2, and K = 4 schedules with m1 = 5, m2 = 10, m3 = 15
and m4 = 20, for a total of 12 combinations. A course consists of five daily consecutive
administrations followed by 28 days of rest as described in the example in Section 2.1, and
schedule k consists of k consecutive courses. Investigators would like to determine which of
the 12 combinations have a DLT rate close to η = 0.30. A maximum of N = 60 patients will
be enrolled. The maximum follow-up time for each patient is ω = 116 days. We consider
the dose-schedule combinations with DLT rates of η ± 0.10 to be acceptable choices of the
MTC, since a small deviation from η is acceptable for the investigators (Braun et al. 2007).
We consider two skeletons that we feel would reflect those most commonly used in
practice. Skeleton 1 specifies the a priori MTC to exist at middle combinations whereas
Skeleton 2 specifies the highest combinations as the a priori MTC. Table 2 gives the values
for the two skeletons, with boldfaced values corresponding to acceptable combinations. For
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each skeleton, we used the methods described in Section 2.5 to calculate the prior means.
For Skeleton 1, this leads to µ0 = −4.80, µ1 = −0.32, µγ = −0.818 and α = 1.73. The
corresponding values for Skeleton 2 were µ0 = −5.50, µ1 = −0.43, µγ = −0.822 and
α = 1.72. With either skeleton, the mode of the hazard function is around four days after
administration.
[Table 2 about here.]
We examined our approach in 15 different scenarios that are summarized in Table 3. The
true DLT rates of every combination of dose and schedule were created from an approach
that we now describe and that is different from the model described in Section 2.3. We let
pdj denote the probability of DLT by ω after a single administration of dose j = 1, 2, 3, and
we let nj denote the number of administrations of dose j received. Then, for a treatment
schedule of n1, n2, and n3 administrations of doses 1, 2, and 3, respectively, regardless of
their order, we denote the actual probability of DLT by time ω as Ptrue(d1, d2, d3, n1, n2, n3).
[Table 3 about here.]
In scenarios 1-4, we assume that all administrations have independent effects (which is
also the assumption used in our model), i.e.
Ptrue(d1, d2, d3, n1, n2, n3) = 1− q
n1
d1
qn2d2 q
n3
d3
, (4)
in which qdj = 1−pdj . In scenarios 5-10, we assume that all administrations have correlated
effects modeled via a Gumbel copula, i.e.
Ptrue(d1, d2, d3, n1, n2, n3) = 1− exp

−
{
3∑
j=1
nj [− log(qdj)]
1/ξ
}ξ , (5)
and is the same as Equation (4) when the correlation parameter ξ = 1. In scenarios 11-15,
we assume that all administrations have correlated effects modeled via a Frank copula, i.e.
Ptrue(d1, d2, d3, n1, n2, n3) = 1 +
1
ξ
log
(
1 +
∏3
j=1[exp(−ξqdj)− 1]
nj
(e−ξ − 1)
∑
j nj−1
)
, (6)
and is the same as Equation(4) when ξ → 0.
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The value of ξ used in each of scenarios 5-15 is shown in the last column of Table 3 and the
actual values of pd1 , pd2 , and pd3 used in each of the fifteen scenarios are shown in the column
labeled “pd” in Table 3. Although Table 3 displays the DLT rates for each of the dose and
schedule combinations under study, the values in the column labeled “pd” can be used to
compute the actual DLT rates for patients who receive a reassignment that does not fit one
of these dose-schedule combinations. For example, suppose we have a patient in scenario 1
who has been assigned to five administrations of 8 mg/m2 and five administrations of 16
mg/m2. This patient has a probability of DLT by ω of 1− (1− 0.010)5(1− 0.013)5 ≈ 0.11.
Table 3 also contains three metrics that seek to measure how difficult finding the MTC
might be in each scenario. The first value, Nc, is the number of combinations with DLT
rates within 10 points of the target η, the second value, MSE, denotes the mean sum-of-
squared-errors for the fit of the linear model log[− log(1− pdj)] = β0 + exp(β1)dj, and the
third value, SD, is the sample standard deviation of the 12 DLT rates. Thus, smaller values
of Nc and SD would indicate greater difficulty of finding the MTC and larger values of
MSE would indicate that the linearity assumed in our model may be suspect and lead to
a poorer ability of correctly identifying an MTC.
We simulated patients to have exponentially distributed inter-arrival times with a mean of
two weeks, and we divided all the follow-up times by 10 to achieve better numeric stability
for our model. When a new patient is enrolled, an interim analysis is performed in which a
single chain of 6, 000 samples, after a burn-in of 4, 000 samples, is drawn from the posterior
distribution for each parameter. These posterior draws are then used to determine the dose
and schedule assigned to the new patient as well as any dose and/or schedule reassignments
for each currently enrolled patient still being followed. We then simulate for each a binary
indicator of DLT using Equation (4), (5), or (6) depending upon the scenario examined. If
a patient is simulated to have a DLT, the time of the DLT is drawn uniformly from the
interval [4 + 24(k − 1), 4 + 24k] under their assigned schedule k, which also implies that
http://biostats.bepress.com/umichbiostat/paper93
19
all possible DLTs occur by ω = 116 days. We did perform simulations of our design using
our assumed model to simulate DLTs and came to similar final conclusions, and we have
omitted those results for brevity.
We compared the performance of our approach that allows for patient reassignment
(Design A) with the traditional approach that does not allow for patient reassignment
(Design B). We evaluated the performance of both approaches in all 15 scenarios by
comparing the correct selection frequency at the end of the study, the mean proportion of
patients assigned to each dose-schedule combination and the mean proportion of patients
who experienced DLTs. We performed 1, 000 simulations in each scenario; our computer
code is available upon request.
3.2 Calibration of Prior Variance
To achieve good operating characteristics, we first calibrated the prior standard deviations
via simulation. We let σ1, σ2 and σ3 have the same value σ to simplify the calibration
process. The prior standard deviation that performs best among σ = 1, 2, 5 would be used
in the study. We certainly could have examined more values of σ, but felt that choosing
among these three values was sufficient and any small deviations in performance with other
possible values for σ were outweighed by the increased amount of simulation time required.
The first row of Figure 1 shows how the prior variance impacts the proportion of patients
assigned to acceptable dose-schedule combinations in Design A using either skeleton 2
(upper left plot) or skeleton 1 (upper right plot). For both skeletons, the design using
σ = 5 performs worse than using σ = 1 or σ = 2 in most of the 15 scenarios. However,
from these two plots, it is not clear which among between σ = 1 and σ = 2 would be
preferred. Therefore, the bottom two plots in Figure 1 attempt to assess the sensitivity of
the results to the chosen skeleton when using σ = 2 (lower left plot) and σ = 1 (lower right
plot). From these two plots, we see that there is greater variation in the results when using
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σ = 1 than σ = 2. We also performed similar analyses for the proportion of simulations
in which acceptable dose-schedule combinations were selected at the end of the study, as
well as repeating our calibration with Design B (no reassignment), and found little change
in our conclusions. Therefore, we selected σ = 2 to be the prior standard deviation used
in the study. And since our design is not sensitive to the skeletons when σ = 2, we have
chosen to use Skeleton 2 in our study.
[Figure 1 about here.]
3.3 Simulation Results
Table 4 contains a summary of the performance of both Design A (with reassignment) and
Design B (without reassignment) in all 15 scenarios described in Table 3. For each design,
this summary is a series of seven columns. The first three columns describe the proportion
of simulations in which the MTC selected at the end of the study had a DLT rate more
than 10 points below the desired DLT rate η (column “L”), within 10 points of η (column
“In”), or more than 10 points above η (column “H”). The next three columns have a similar
interpretation related to the average percentage of dose-schedule assignments during the
study. The seventh column, labeled “DLT” is the average of the proportion of observed
DLTs among the 1,000 simulations. The summary for Design A contains an additional
column, labeled “Rn”, which is the average proportion of patients receiving at least one
reassignment during the study.
Overall, we are able to identify acceptable dose-schedule combinations at the end of the
study in a majority of simulations in all 15 scenarios, whether or not reassignment is used.
This is not surprising, as the primary goal of reassignment is to optimize the assignments
of patients enrolled in the study, rather than improve the final decision at the end of the
study. Scenarios 4, 8, 9, and 10 have the lowest percentages of identifying the MTC at an
acceptable combination, which is partially explained by the fact that these scenarios have
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only 1 or 2 acceptable combinations to choose from. These scenarios also have some of the
largest values of MSE, indicating that the assumption of linearity in our model is suspect.
Nonetheless, we emphasize that all 15 scenarios have DLT rates that come from models
that are different from our assumed model, so that our approach works well even when the
model is misspecified.
With regard to patient assignments during the study, we see that including reassignment
leads to a higher proportion of patients assigned to acceptable combinations than with-
out reassignment. For example, in scenario 4, Design A assigned 55% of the patients to
acceptable combinations, compared with only 30% for Design B, and the corresponding
percentages in scenario 10 are 52% and 27%, respectively. Moreover, in all 15 scenarios, the
average DLT rate when using reassignment is never more than the average observed DLT
rate without reassignment and is always close to the desired DLT rate. The one possible
exception is scenario 7, which had an average observed DLT rate of 0.38, which might seem
higher than desired. However, in Table 3 we see that all combinations in scenario 7 have
DLT rates of 0.30 or more, so it is not surprising that a higher than desired DLT rate was
observed.
With regard to patient reassignment, we see that the proportion of reassignments varied
among the 15 scenarios from 0.20 in scenario 7 to 0.69 in scenario 4. The lowest rates of
reassignment were seen in scenarios 1, 7 and 9; a common feature of these three scenarios
is that most of the dose-schedule combinations are either toxic or inefficacious. Rates of
reassignment above 0.60 were seen in scenarios 4, 8, 10, 11, and 15. Although the explanation
for the high rate of reassignment is not immediately obvious, it may be partially due to the
fact that acceptable combinations in these scenarios appear with longer schedules of the
highest dose, with even longer schedules then becoming overly toxic. This is contrasted to
scenario 1, which has a much lower rate of reassignment because there are no overly toxic
combinations.
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[Table 4 about here.]
Recall that we found that using a value of σ = 2 for the prior variances of the model
parameters was insensitive to the skeleton used. To confirm this statement, we do not
present the results when using Skeleton 1 in a tabular format like that of Table 4. Instead,
Figure 2 contains a visual summary of the percentage of simulations in which the MTC was
selected at an acceptable combination (left plot) and the percentage of patients assigned
to acceptable combinations (right plot) in each of the 15 scenarios. As we found in Table
4, we are able to identify the MTC well whether or not reassignment is allowed, but that
inclusion of reassignment greatly improves the treatment assignment of patients enrolled
in the study.
[Figure 2 about here.]
4. DISCUSSION
In this work, we have contributed to the existing literature on the design of dose- and
schedule-finding studies by first expanding the schedule-finding model used by Liu and
Braun (2009) to incorporate variations in dose and have then incorporated an algorithm for
assessing whether or not currently enrolled patients should have their assigned dose and/or
schedule changed to one with an estimated DLT closer to that desired. We modeled the
per-administration dose as a covariate through the cure parameter of the hazard function
for a single administration in the framework of the cure rate model, which is particularly
attractive as a significant number of patients would not have DLTs from a new agent.
While the functional form of the hazard function of a single administration can be chosen
to reflect the background of a specific study, another major advantage of our method lies in
the flexibility to model any sequence of dose and administration combinations. Furthermore,
we have proposed an algorithm to optimize the intra-patient dose-schedule reassignment
in addition to the conventional method for inter-patient optimization. Simulations indicate
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that our design identifies correct dose and schedule combinations as well as the traditional
method that does not allow for intra-patient doses-schedule reassignments, but with a larger
number of patients assigned to those combinations.
As we stated earlier, we have chosen to assess the need to reassign the dose and/or
schedule of each enrolled patient only when a new patient is enrolled because we believe
this approach optimizes the treatment of each patient as much as possible yet still is based
upon a feasible level of computation. In our simulations, with an average arrival of a new
patient every 14 days relative to a follow-up of 116 days, we had to consider no more
than approximately eight reassignments with each new enrollment. In a study with much
faster accrual, there would be many more possible reassignments to consider at each new
enrollment and many of the patients could have several reassignments occurring during
their treatment. Investigators may feel that this level of possible reassignment impractical,
requiring a different rule for determining when reassignment is possible. An interesting
area of research is to compare our approach to other reassignment strategies to determine
when fewer reassignments are allowed, yet do not lead to significantly worsened operating
characteristics.
And though we introduce our design in the setting of dose-schedule finding studies, our
methods could be easily applied to other settings. If the schedule were fixed while the dose
varied, our design would be similar to the TITE-CRM in which the weight function would
be determined by the functional form of the hazard function of a single administration
in our model. Our methods are also applicable to trials studying non-nested schedules
like that in Li, Bekele, and Cook (2008), although since there is no natural order for
non-nested schedules, our approach could be modified to only allow reassignment of doses
but not schedules. In Phase I/II studies, one can easily adapt our method to the work
of Yuan and Yin (2009) to model late-onset toxicity/efficacy and introduce intra-patient
dose/schedule changes. Similar modifications could be made to apply our approach to
Hosted by The Berkeley Electronic Press
24
trials of combinations of two agents by specifying the hazard function of the toxicity or
efficacy after a single administration to be a function of doses of both agents. However, the
model that takes account of the joint distribution of toxicity and efficacy as a function of
possibly multiple doses is not immediately obvious and should be carefully chosen. Lastly,
even in a trial with a fixed schedule and multiple doses, one might still want to add more
administrations later to patients with neither toxicity nor efficacy (Fan and Wang 2007) in
efforts of increasing the probability of efficacy. Our model could be used to determine the
number of additional administrations and the dose for each administration adaptively.
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Figure 1. Impact of prior standard deviation and skeletons on the MTC assignment for
Design A.
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Figure 2. Comparison between Design A and B using Skeleton 1 and calibrated prior
standard deviation 2.
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Table 1. Nine possible remaining dose and schedule assignments for a hypothetical patient who has not completed
their originally assigned treatment and remains under observation without DLT. Vectors of remaining administration
times are s(3)!+ = {58, 59, 60}, s
(4)
!+ = {s
(3)
!+ , 84, 85, 86, 87, 88}, and s
(5)
!+ = {s
(4)
!+ , 112, 113, 114, 115, 116}
.
Dose at Each Times of
Decision Administration Administration
No change 32 s(3)$+
Change dose only 8 s(3)$+
16 s(3)$+
Change schedule only 32 s(4)$+
32 s(5)$+
Change dose & schedule 8 s(4)$+
8 s(5)$+
16 s(4)$+
16 s(5)$+
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Table 2. The two skeletons used in the simulation study. The boldfaced values correspond to acceptable combina-
tions.
Schedule
Skeleton Dose(mg/m2) 1 2 3 4
1 8 0.03 0.12 0.30 0.50
16 0.15 0.30 0.50 0.60
24 0.30 0.50 0.60 0.75
2 8 0.02 0.06 0.15 0.25
16 0.08 0.15 0.25 0.30
24 0.15 0.25 0.30 0.33
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Table 3. Summary of the 15 scenarios studied, including the actual DLT rates of each dose and schedule combination
and three metrics that measure the difficulty of identifying an MTC. Boldfaced values indicate dose and schedule
combinations with DLT rates within 10 points of the desired DLT rate η = 0.30.
Schedule
Method Scenario Dose(mg/m2) 1 2 3 4 pd Nc MSE SD ξ
Independent 1 8 0.05 0.10 0.14 0.18 0.010 3 0.03 0.08 n/a
16 0.06 0.12 0.18 0.23 0.013
32 0.90 0.17 0.24 0.30 0.018
2 8 0.05 0.10 0.14 0.18 0.010 3 0.32 0.23 n/a
16 0.09 0.17 0.24 0.30 0.018
32 0.30 0.52 0.66 0.77 0.070
3 8 0.02 0.05 0.07 0.10 0.005 1 0.35 0.32 n/a
16 0.18 0.32 0.44 0.54 0.038
32 0.47 0.72 0.85 0.92 0.120
4 8 0.03 0.07 0.10 0.13 0.007 1 0.42 0.15 n/a
16 0.05 0.09 0.13 0.17 .0095
32 0.17 0.31 0.42 0.52 0.036
Gumbel 5 8 0.18 0.31 0.41 0.50 0.048 4 0.06 0.16 0.88
16 0.22 0.36 0.48 0.57 0.058
32 0.29 0.47 0.59 0.69 0.080
6 8 0.13 0.18 0.23 0.27 0.050 3 0.30 0.20 0.60
16 0.33 0.45 0.54 0.60 0.140
32 0.43 0.57 0.66 0.72 0.190
7 8 0.30 0.44 0.54 0.61 0.110 2 0.07 0.15 0.70
16 0.35 0.50 0.60 0.68 0.130
32 0.46 0.63 0.73 0.80 0.180
8 8 0.02 0.06 0.11 0.17 .0021 2 0.22 0.18 1.5
16 0.07 0.17 0.30 0.42 0.006
32 0.11 0.27 0.44 0.59 0.010
9 8 0.17 0.28 0.36 0.43 0.049 2 0.29 0.25 0.81
16 0.43 0.62 0.74 0.82 0.140
32 0.56 0.76 0.86 0.92 0.200
10 8 0.02 0.06 0.10 0.15 .0018 1 0.29 0.12 1.5
16 0.03 0.07 0.13 0.17 .0023
32 0.07 0.17 0.30 0.42 0.006
Frank 11 8 0.05 0.09 0.13 0.17 0.010 3 0.03 0.14 1.5
16 0.09 0.17 0.24 0.30 0.020
32 0.19 0.32 0.42 0.50 0.043
12 8 0.19 0.32 0.43 0.51 0.044 3 0.08 0.16 1.5
16 0.26 0.43 0.54 0.63 0.065
32 0.31 0.49 0.61 0.69 0.080
13 8 0.07 0.13 0.18 0.23 .0146 3 0.13 0.21 1.5
16 0.18 0.31 0.41 0.49 0.042
32 0.33 0.52 0.64 0.72 0.087
14 8 0.18 0.31 0.41 0.49 0.042 2 0.04 0.19 1.5
16 0.29 0.47 0.59 0.67 0.075
32 0.42 0.62 0.74 0.82 0.120
15 8 0.03 0.06 0.08 0.11 0.006 2 0.31 0.13 1.5
16 0.05 0.09 0.13 0.17 0.010
32 0.15 0.27 0.36 0.44 0.035
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Table 4. Simulation results for Design A and B using prior standard deviation σ = 2 and Skeleton 2. For each design,
columns “Selection” gives the percentage of identifying three categories of combinations as the MTC: unacceptable
inefficacious combinations (“L”) ; acceptable combinations (“In”) and too toxic combinations (“H”). For each design,
columns “Assignment” gives the mean proportion of patients assigned to the three categories, columns “DLT” give
the mean proportion of patients who experienced DLTs and the column “Rn” gives the mean proportion of patients
whose experienced dose or schedule reassignment.
Design A (With Reassignment) Design B (Without Reassignment)
Selection Assignment DLT Rn Selection Assignment DLT
Scenario L In H L In H L In H L In H
1 6 94 0 10 90 0 27 38 4 96 0 13 87 0 27
2 14 83 3 20 63 18 32 56 12 86 3 28 53 18 32
3 17 70 14 22 52 27 32 52 27 62 11 27 50 23 33
4 27 56 17 20 55 25 30 69 31 52 17 37 30 33 30
5 3 82 15 8 63 28 35 43 2 81 17 7 63 32 37
6 14 61 25 18 52 30 35 44 10 65 25 20 42 38 35
7 0 80 20 0 67 33 38 20 0 75 25 0 60 40 40
8 12 57 31 13 57 30 32 73 18 57 26 27 37 35 32
9 20 51 29 21 39 40 35 26 17 55 28 20 40 40 37
10 25 54 21 17 52 32 30 62 29 51 20 32 27 42 30
11 11 78 11 15 62 23 32 66 12 78 11 23 48 30 32
12 6 77 17 10 58 30 35 45 6 75 19 10 52 38 37
13 16 68 16 15 62 23 33 56 15 69 16 23 52 25 33
14 10 60 29 13 58 30 35 39 9 56 34 13 52 37 37
15 16 76 8 17 62 22 30 64 29 63 9 27 43 28 30
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